Alembic rides generic Abilify wave amid compliance wins
This article was originally published in Scrip
Executive Summary
Shares of Alembic Pharmaceuticals surged on Indian bourses, after the US FDA cleared the first set of generic versions of Otsuka's schizophrenia and bipolar disorder drug Abilify (aripiprazole).
You may also be interested in...
Torrent On Course For Buy, US Momentum
Torrent Pharmaceuticals Ltd may have opted out of the race for the injectables firm Gland Pharma Ltd, but the Indian company stays interested in a buy to build its "hospital presence".
Alembic Setting Up For US Oncology Play
Alembic Pharmaceuticals, which has seen a dazzling FY16, appears set to build on its strong showing in the US with plans for filings in the oncology and dermatology space and a potential ramp up of its own label products there.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.